Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfex-based Conditioning for Allogeneic HCT in Hematologic Disorders
NCT00448357Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2005
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan in chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), acute myeloid leukemia (AML), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Oct 2005; status: completed.
02
Drugs
busulfan
03
Conditions
chronic lymphocytic leukemia (CLL)chronic myelogenous leukemia (CML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00448357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448357.